Hao-Ming Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hao-Ming Lin has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Rui Zhang
Sun Yat-Sen Memorial Hospital 2 Department of Biliary-Pancreatic Surgery , Guangzhou, China
3 shared publications Rui Zhang
Sun Yat Sen Univ, HBP Surg Dept, Sun Yat Sen Mem Hosp, 107 Yan Jiang West Rd, Guangzhou 510289, Peoples R China
2 shared publications- Wenrui Wu
Department of Pancreato-Biliary Surgery
2 shared publications Cai-Ni Yang
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publicationChao Liu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China
1 shared publication- Chao Liu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Hepato-Pancreato-Biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 28 February 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-10
Efficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study
Gallbladder carcinoma (GBC) is an extremely aggressive tumor of the biliary tract with a bleak prognosis, and the evidence supporting the benefit of available systemic therapy for advanced GBC is scarce. Herein, this study intended to investigate the real-world outcome of chemotherapy combined with programmed death-1 (PD-1) inhibitor for the management of unresectable or recurrent GBC. From January 2018 to December 2023, consecutive patients who were treated with systematic treatment, including chemotherapy or the combination of chemotherapy plus PD-1 inhibitor, for unresectable or recurrent GBC were retrospectively identified. Clinical data regarding baseline characteristics, therapeutic response, adverse events (AEs), and oncological outcomes were collected. The eligible patients were allocated to combination therapy arm (n = 46) and mono-chemotherapy arm (n = 19). After propensity score matching (PSM), 16 patients were allocated in each arm. The overall survival (OS) and progression-free survival (PFS) of combination therapy were marginally superior to mono-chemotherapy both before and after PSM. The combination therapy exhibited advantage over mono-chemotherapy in regards to partial response (PR) (before PSM: P = 0.009; after PSM: P = 0.037) and objective response rate (ORR) (before PSM: P = 0.006; after PSM: P = 0.015). In combined therapy cohort, 1 patient achieve a complete response, and 13 patients were assessed as appropriate for surgical excision, among which 1 patient refused further surgical intervention. In patients with unresectable or recurrent GBC, the combination of chemotherapy and PD-1 inhibitor as first-line therapy exhibited prolonged OS and PFS, and increased PR and ORR over those receiving chemotherapy alone, with an acceptable toxicity profile. The combination therapy may be a potential conversion therapy in unresectable GBC patients.
- 28 February 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-10
Open AccessEfficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study
Gallbladder carcinoma (GBC) is an extremely aggressive tumor of the biliary tract with a bleak prognosis, and the evidence supporting the benefit of available systemic therapy for advanced GBC is scarce. Herein, this study intended to investigate the real-world outcome of chemotherapy combined with programmed death-1 (PD-1) inhibitor for the management of unresectable or recurrent GBC. From January 2018 to December 2023, consecutive patients who were treated with systematic treatment, including chemotherapy or the combination of chemotherapy plus PD-1 inhibitor, for unresectable or recurrent GBC were retrospectively identified. Clinical data regarding baseline characteristics, therapeutic response, adverse events (AEs), and oncological outcomes were collected. The eligible patients were allocated to combination therapy arm (n = 46) and mono-chemotherapy arm (n = 19). After propensity score matching (PSM), 16 patients were allocated in each arm. The overall survival (OS) and progression-free survival (PFS) of combination therapy were marginally superior to mono-chemotherapy both before and after PSM. The combination therapy exhibited advantage over mono-chemotherapy in regards to partial response (PR) (before PSM: P = 0.009; after PSM: P = 0.037) and objective response rate (ORR) (before PSM: P = 0.006; after PSM: P = 0.015). In combined therapy cohort, 1 patient achieve a complete response, and 13 patients were assessed as appropriate for surgical excision, among which 1 patient refused further surgical intervention. In patients with unresectable or recurrent GBC, the combination of chemotherapy and PD-1 inhibitor as first-line therapy exhibited prolonged OS and PFS, and increased PR and ORR over those receiving chemotherapy alone, with an acceptable toxicity profile. The combination therapy may be a potential conversion therapy in unresectable GBC patients.
- Open Access
- 22 October 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (8) , 3046-3051
The clinical effect of primary duct closure and T-tube drainage: A propensity score matched study
- 22 October 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (8) , 3046-3051
Open AccessThe clinical effect of primary duct closure and T-tube drainage: A propensity score matched study
- Open Access
- 1 December 2021
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 12 (6) , 2985-2998
Screening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma
Screening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma Wei Chen, Ming-Juan Hu, Xiao-Lan Zhong, Lin-Hua Ji, Jian Wang, Cheng-Fang Zhang, Rui Zhang, Hao-Ming Lin
- 1 December 2021
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 12 (6) , 2985-2998
Open AccessScreening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma
Screening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma Wei Chen, Ming-Juan Hu, Xiao-Lan Zhong, Lin-Hua Ji, Jian Wang, Cheng-Fang Zhang, Rui Zhang, Hao-Ming Lin
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
miR‐4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A
Hepatocellular carcinoma (HCC) has high morbidity and mortality. MicroRNAs (miRNAs), which could be regulated by cancer‐derived exosomes, play critical regulatory roles in the initiation and development of cancer. However, the expressions, effects, and mechanisms of abundant miRNAs regulated by HCC cancer‐derived exosomes in HCC remain largely unclear. Exosomes of HepG2 cells under heat shock, TGF‐β1, doxorubicin, acid and hypoxia/reoxygenation (H/R) conditions, and exosomes were successfully identified by transmission electron microscopy and Western blot analysis. The identified exosomes were then applied to evaluate the miRNA expression profiles by RNA sequencing. Mechanically, we discovered that doxorubicin was upregulated, TGF‐β1 downregulated the expressions of Vps4A, Rab27A, Alix, and Hrs in HepG2 cells and exosomes, and Vps4A and Rab27A, as target genes for miR‐4454, could also be downregulated by miR‐4454. Functionally, we revealed that miR‐4454 inhibitor and miR‐4454 inhibitor‐mediated exosomes could markedly suppress proliferation, migration, invasion, and vascularization and accelerate cycle arrest, apoptosis, and ROS of HepG2 cells. This study provided many potential HCC cancer‐derived exosome‐mediated miRNAs in HCC under 5 different stimulus conditions. Meanwhile, we certified that miR‐4454 in exosomes could provide a novel and effective mechanism for HCC function.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessmiR‐4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A
Hepatocellular carcinoma (HCC) has high morbidity and mortality. MicroRNAs (miRNAs), which could be regulated by cancer‐derived exosomes, play critical regulatory roles in the initiation and development of cancer. However, the expressions, effects, and mechanisms of abundant miRNAs regulated by HCC cancer‐derived exosomes in HCC remain largely unclear. Exosomes of HepG2 cells under heat shock, TGF‐β1, doxorubicin, acid and hypoxia/reoxygenation (H/R) conditions, and exosomes were successfully identified by transmission electron microscopy and Western blot analysis. The identified exosomes were then applied to evaluate the miRNA expression profiles by RNA sequencing. Mechanically, we discovered that doxorubicin was upregulated, TGF‐β1 downregulated the expressions of Vps4A, Rab27A, Alix, and Hrs in HepG2 cells and exosomes, and Vps4A and Rab27A, as target genes for miR‐4454, could also be downregulated by miR‐4454. Functionally, we revealed that miR‐4454 inhibitor and miR‐4454 inhibitor‐mediated exosomes could markedly suppress proliferation, migration, invasion, and vascularization and accelerate cycle arrest, apoptosis, and ROS of HepG2 cells. This study provided many potential HCC cancer‐derived exosome‐mediated miRNAs in HCC under 5 different stimulus conditions. Meanwhile, we certified that miR‐4454 in exosomes could provide a novel and effective mechanism for HCC function.
- 1 July 2020
- Published by Elsevier in Cancer Genetics
- Vol. 245, 27-34
Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma
- 1 July 2020
- Published by Elsevier in Cancer Genetics
- Vol. 245, 27-34
Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma
- 17 July 2019
- Published by Springer Nature in Science China Life Sciences
- Vol. 63 (5) , 764-770
Clinical strategies for differentiating IgG4-related cholecystitis from gallbladder carcinoma to avoid unnecessary surgical resection
Immunoglobulin G4 (IgG4)-related cholecystitis (IgG4-C) is often difficult to distinguish from gallbladder carcinoma (GBC). This study aimed to determine a practical strategy for differentiating between IgG4-C and GBC to avoid unnecessary surgical resection. The expression of IgG4 in the gallbladder was detected by immunohistochemistry. The clinicopathological and radiological characteristics of IgG4-C patients and GBC patients were analyzed retrospectively. Immunohistochemistry revealed that IgG4 was upregulated in the plasma cells of IgG4-C tissues. The median serum total bilirubin levels were significantly higher in the patients with IgG4-C than in those with GBC (45.8 µmol L−1 vs. 29.9 µmol L−1). The serum γ-GGT levels were higher in IgG4-C patients than in GBC patients, whereas the serum levels of CA125 were significantly higher in GBC patients than in IgG4-C patients. The imaging scans were helpful for differentiating IgG4-C from GBC based on the presence of a layered pattern and Rokitansky-Aschoff sinuses in the gallbladder wall. There were no statistically significant differences in age, presence of abdominal pain, level of emaciation between the two groups. Our study demonstrated that the combination of imaging with serum total bilirubin, γ-GGT and CA125 levels can offer added preoperative diagnostic value and reduce the rate of IgG4-C misdiagnosis.
- 17 July 2019
- Published by Springer Nature in Science China Life Sciences
- Vol. 63 (5) , 764-770
Clinical strategies for differentiating IgG4-related cholecystitis from gallbladder carcinoma to avoid unnecessary surgical resection
Immunoglobulin G4 (IgG4)-related cholecystitis (IgG4-C) is often difficult to distinguish from gallbladder carcinoma (GBC). This study aimed to determine a practical strategy for differentiating between IgG4-C and GBC to avoid unnecessary surgical resection. The expression of IgG4 in the gallbladder was detected by immunohistochemistry. The clinicopathological and radiological characteristics of IgG4-C patients and GBC patients were analyzed retrospectively. Immunohistochemistry revealed that IgG4 was upregulated in the plasma cells of IgG4-C tissues. The median serum total bilirubin levels were significantly higher in the patients with IgG4-C than in those with GBC (45.8 µmol L−1 vs. 29.9 µmol L−1). The serum γ-GGT levels were higher in IgG4-C patients than in GBC patients, whereas the serum levels of CA125 were significantly higher in GBC patients than in IgG4-C patients. The imaging scans were helpful for differentiating IgG4-C from GBC based on the presence of a layered pattern and Rokitansky-Aschoff sinuses in the gallbladder wall. There were no statistically significant differences in age, presence of abdominal pain, level of emaciation between the two groups. Our study demonstrated that the combination of imaging with serum total bilirubin, γ-GGT and CA125 levels can offer added preoperative diagnostic value and reduce the rate of IgG4-C misdiagnosis.